Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Abbott Labs

Fund managers have historically pivoted to top dividend stocks in low-interest-rate environments. With the Fed poised to start cutting interest rates within the next eight to 12 months, these two blue chip dividend stocks could be compelling buys.

These Dividend Stocks Are an Investor's Best Friend

Medical device stocks have underperformed the broader market, with the iShares U.S. Medical Devices ETF up only 1% in the past year. Medtronic, a dividend aristocrat, has shown decent organic revenue growth in the last five quarters, but the stock price continues to sag. With EPS growth expected in FY 2025, I highlight key price levels on the chart to monitor ahead of Q4 2024 results next week.

Medtronic: Looking Ahead To FY 2025 EPS Growth, Shareholder Friendly Actions

In the closing of the recent trading day, Medtronic (MDT) stood at $83.52, denoting a +0.82% change from the preceding trading day.

Medtronic (MDT) Advances While Market Declines: Some Information for Investors

Medtronic is a leading global medical technology company with diversified revenue streams across multiple segments. Medtronic has made significant strides in bolstering its product portfolio and strategic initiatives, positioning it for long-term growth. According to my DCF model, MDT is currently undervalued by around 26.4%. The development of EV/EBITDA confirms the result of my intrinsic value calculation.

Medtronic Stock Looks Promising Before Fiscal Q4 2024 Release

Medtronic's (MDT) rapid cadence of new product approvals is a strong foundation for future growth. However, the company also navigates some macroeconomic challenges.

Here's How Medtronic (MDT) Is Placed Ahead of Q4 Earnings

Shares in Arecor Therapeutics PLC (AIM:AREC) rose in the wake of news it is teaming with US med-tech giant Medtronic to develop a new, high-concentration, thermostable insulin designed specifically for use in the latter's next-generation implantable insulin pumps. Arecor believes there is the potential for 'significant advancements' in treatment for a group of diabetes patients who find limited benefits from conventional therapies.

Arecor shares higher after Medtronic deal; broker remains upbeat

DUBLIN , May 9, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2024 on Thursday, May 23, 2024. A news release will be issued at approximately 5:45 a.m.

Medtronic to announce financial results for its fourth quarter and full fiscal year 2024

Arecor Therapeutics plc (“Arecor” or the “Company”) ARECOR AND MEDTRONIC DIABETES ESTABLISH COLLABORATION TO DEVELOP A NOVEL THERMOSTABLE INSULIN FOR IMPLANTABLE PUMP DELIVERY Medtronic to fund Arecor's development of Arestat™ enabled novel, high concentration, thermostable insulin, specifically tailored for use in combination with a next-generation implantable pump Cambridge, UK, 9 May 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announced a research collaboration with Medtronic plc (NYSE: MDT), a global leader in healthcare technology, to develop a novel, high concentration, thermostable insulin for use by Medtronic's Diabetes business in a next-generation implantable pump. This new insulin has the potential to bring significant advancements in the current insulin treatment options for a small population of patients who have limited options for controlling their diabetes with traditional therapy.

Arecor and Medtronic Diabetes establish collaboration to develop a novel thermostable insulin for implantable pump delivery

Arecor Therapeutics PLC (AIM:AREC) said it is teaming with US med-tech giant Medtronic to develop a new, high-concentration, thermostable insulin designed specifically for use in the latter's next-generation implantable insulin pumps. Arecor believes there is the potential for 'significant advancements' in treatment for a group of diabetes patients who find limited benefits from conventional therapies.

Arecor Therapeutics agrees insulin tie-up with US med-tech giant Medtronic

Recently, Zacks.com users have been paying close attention to Medtronic (MDT). This makes it worthwhile to examine what the stock has in store.

Medtronic PLC (MDT) is Attracting Investor Attention: Here is What You Should Know

Medtronic (MDT) closed at $80.86 in the latest trading session, marking a +1.4% move from the prior day.

Medtronic (MDT) Rises Higher Than Market: Key Facts

Air Products and Chemicals

Franklin Resources

C.H. Robinson Worldwide

Cincinnati Financial

Clorox

Hormel Foods

McCormick

NextEra Energy

Realty Income Corp

Stanley Black & Decker

Sysco

Target

T. Rowe Price Group

The ProShares S&P 500 Dividend Aristocrats ETF performed well in March, finishing up 4.60%. Some of these gains have been erased in April, though. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term.

My Best Dividend Aristocrats For May 2024

Closed-loop sensing capability instantly and automatically adjusts therapy while treating chronic pain DUBLIN , April 26, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the U.S. Food and Drug Administration (FDA) has approved the Inceptiv™ closed-loop rechargeable spinal cord stimulator (SCS) for the treatment of chronic pain. Inceptiv is the first Medtronic SCS device to offer a closed-loop feature that senses biological signals along the spinal cord and automatically adjusts stimulation in real time, keeping therapy in harmony with the motions of daily life.

Medtronic receives FDA approval for Inceptiv™ closed-loop spinal cord stimulator

Zacks.com users have recently been watching Medtronic (MDT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Medtronic PLC (MDT) Is a Trending Stock: Facts to Know Before Betting on It

Moderna

Stryker

While artificial intelligence may be useful for a variety of purposes – including asking silly questions we're afraid to pose in real life – the ultimate end game for digital intelligence could be to advance the human condition, which brings us to medical AI stocks. When conducted in a controlled environment, AI can help accelerate productivity.

Medical AI Could Be Your Ticket to Riches: 3 Stocks to Buy

Medtronic (MDT) reachead $80.57 at the closing of the latest trading day, reflecting a +1.37% change compared to its last close.

Medtronic (MDT) Laps the Stock Market: Here's Why

Investors continue to be optimistic about Medtronic (MDT) due to the strength of its Neurosurgery and Cardiovascular portfolios.

Here's Why You Should Retain Medtronic (MDT) Stock for Now

The medical device maker's growth rate has averaged less than 2% in the past five years. However, it's still innovating and recently launched an AI-assisted endoscopy system.

Medtronic Stock: Buy, Sell, or Hold?

According to a new survey from Medtronic and Morning Consult, nearly two-thirds of U.S. adults say they'd opt for a shorter, healthier life than a longer one with health issues DUBLIN , April 17, 2024 /PRNewswire/ -- Americans overwhelmingly say that when they think about longevity, it's more than just living longer—it's about living their healthiest, best lives. While most want to live to 90—well past the average  U.S. life expectancy  of 77.5 years—nearly two-thirds (66%) would choose a shorter, healthier life over a longer one with health issues.

Americans favor quality over quantity in pursuit of longevity

Archer-Daniels-Midland Company

S&P Global

Although dividend investing has plenty of research backing its efficacy, it's a slow burn. Further, it may incur high opportunity costs during broad-market rallies, such as what we saw during the bull in the Nasdaq last year.

Cash Burn: 3 Dividend Aristocrats to Dump for Buyback Plays

AI could solve one of the biggest problems in drug development: the lengthy time it takes to bring a product to market. The AI in healthcare market is set to expand at a compound annual growth rate of nearly 50%.

2 Artificial Intelligence (AI) in Healthcare Stocks to Buy and Hold for Great Long-Term Potential

Medtronic is a healthcare technology company that has seen encouraging growth in the current fiscal year. The company has maintained pricing power and has a strong balance sheet, with an A+ grade for profitability. Medtronic is well-positioned for future opportunities, including diabetes care, and is undervalued compared to historical norms with a decent starting dividend yield.

Medtronic: Dividend Aristocrat Value In Plain Sight

Medtronic is undervalued compared to its long-term P/E ratio and has potential for strong returns. The company's focus on innovation and product diversification positions it well for future growth.

35% Undervalued? Medtronic's Future Looks Very Bright

Dublin, Ireland--(Newsfile Corp. - April 12, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announces that Medtronic plc (NYSE: MDT), a global leader in healthcare technology, presented at the Genius Summit 2024 the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system developed by Cosmo IMD, along with a new strategic collaboration designed to enhance patient care.

Cosmo and Medtronic Unveil the Future of AI in GI: Genius Summit 2024 Reveals Innovations and Collaborations That Advance Endoscopic Care

Medtronic's (MDT) Sphere-360 catheter is designed to simplify the atrial fibrillation process while increasing efficiency and giving long-lasting lesions.

News for Medtronic Stock (MDT)